Innovations in Corneal Crosslinking.


Journal

Current eye research
ISSN: 1460-2202
Titre abrégé: Curr Eye Res
Pays: England
ID NLM: 8104312

Informations de publication

Date de publication:
02 2023
Historique:
pubmed: 3 12 2022
medline: 9 2 2023
entrez: 2 12 2022
Statut: ppublish

Résumé

Corneal Crosslinking (CXL) strengthens the keratoconus cornea and prevents further disease progression. Modified crosslinking protocols and different riboflavin solutions have been proposed to optimize the procedure and improve treatment success. PubMed research of relevant publications and report of own experiences with different CXL protocols. Accelerated CXL shows comparable efficiency with shorter surgery time and similar complication rates. Customized CXL provides improved results with faster epithelial healing. CXL in a hyperoxic environment seems to be a safe and effective transepithelial alternative with presumably less complications and fewer side effects. Thin corneas (<400 µm) can be treated safely by corneal swelling using hypoosmolar riboflavin solutions and reducing the applied UV-energy. The combination of CXL with photorefractive keratectomy (PRK) can be considered in patients with contact lens intolerance improving visual acuity, however, with increased risk of visual loss compared to CXL alone. Two-Photon (2Ph) CXL is a promising new technology enabling three-dimensional CXL. Recently developed CXL protocols offer advantages over the standard "Dresden-protocol" and should be considered in patients with progressive keratectasia.

Identifiants

pubmed: 36458595
doi: 10.1080/02713683.2022.2146725
doi:

Substances chimiques

Photosensitizing Agents 0
Riboflavin TLM2976OFR
Cross-Linking Reagents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

144-151

Auteurs

Klara Borgardts (K)

Department of Ophthalmology, University Hospital Düsseldorf, Düsseldorf, Germany.

Johannes Menzel-Severing (J)

Department of Ophthalmology, University Hospital Düsseldorf, Düsseldorf, Germany.

Isaak Fischinger (I)

Institut für Refraktive and Ophthalmo-Chirurgie (IROC), Zürich, Switzerland.
Department of Ophthalmology, Kepler University Hospital, Linz, Austria.
Medical Faculty, Johannes Kepler University Linz, Linz, Austria.

Gerd Geerling (G)

Department of Ophthalmology, University Hospital Düsseldorf, Düsseldorf, Germany.

Theo G Seiler (TG)

Department of Ophthalmology, University Hospital Düsseldorf, Düsseldorf, Germany.
Institut für Refraktive and Ophthalmo-Chirurgie (IROC), Zürich, Switzerland.
Department of Ophthalmology, Inselspital, Bern University Hospital, Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH